Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    NCT01476163
Previous Study | Return to List | Next Study

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Expanded access is currently available for this treatment.
Verified November 2016 by Amicus Therapeutics
Sponsor:
Information provided by (Responsible Party):
Amicus Therapeutics
ClinicalTrials.gov Identifier:
NCT01476163
First received: November 17, 2011
Last updated: November 9, 2016
Last verified: November 2016
  Purpose
This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry disease. Treatment is open label for 6 months with renewal every 6 months.

Condition Intervention Phase
Fabry Disease
Drug: migalastat HCl
Phase 3

Study Type: Expanded Access     What is Expanded Access?
Official Title: Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)

Resource links provided by NLM:


Further study details as provided by Amicus Therapeutics:

Study Start Date: December 2011
Estimated Study Completion Date: October 2016
Estimated Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: migalastat HCl
    150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
    Other Name: AT1001, migalastat
Detailed Description:
This Physician Initiated Request program allows physicians to request permission from Amicus to receive migalastat HCl for specific patients with Fabry disease who have a mutation amenable to this treatment, who do not have access to available treatment alternatives, or do not meet requirements for participation in an existing migalastat clinical study. Up to 20 patients worldwide may be treated. Patients must meet specific criteria to receive Amicus permission for participation. Key criteria for participation include: 16-74 years old; Confirmed GLA gene mutation shown to be responsive to migalastat; Have no treatment option because either unsuitable for enzyme replacement therapy (ERT) or unable to access ERT. Requirements for sufficient kidney function. If permission is granted, initial approval is for a 6 month supply of migalastat HCl with renewal every 6 months available upon meeting continued eligibility.
  Eligibility

Ages Eligible for Study:   16 Years to 74 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic kidney (HEK-293) cell-based assay
  • 16-74 years of age
  • Strong clinical indication for treatment of Fabry disease
  • No other treatment option including either unsuitable for ERT or unable to access ERT
  • Appropriate female and male contraception
  • Willing to receive treatment with migalastat HCl via this program including having signed an authorization for sharing clinical data

Exclusion Criteria:

  • Estimated glomerular filtration rate (eGFR) or GFR <30 mL/minute
  • Scheduled for renal or other organ transplant or replacement therapy
  • Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy FABRAZYME® (agalsidase beta) or REPLAGAL™ (agalsidase alpha)
  • Contraindication to migalastat, i.e., sensitivity to other iminosugar such as miglustat, miglitol
  • Treated with another investigational drug within 30 days of start of migalastat HCl treatment
  • Unable to comply with study requirements or deemed otherwise unsuitable for study entry in the opinion of the investigator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01476163

Contacts
Contact: Amicus Therapeutics Patient Advocacy clinicaltrials@amicusrx.com

Locations
United States, California
CHOC Children's Hospital Division of Metabolic Disease
Orange, California, United States, 92868
Contact: Nina Movsesyan, PhD    714-509-3008    nmovsesyan@CHOC.org   
Principal Investigator: Raymond Y Wang, MD         
United States, Massachusetts
Renal and Transplant Associates of New England, PC
Springfield, Massachusetts, United States, 01107
Contact: Gregory L Braden, MD    413-794-5548    Gregory.Braden@baystatehealth.org   
Contact: Joy Whitbeck    (413) 731-1008 ext 700    Joy@kidneymd.us   
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Contact: Amy C Yang, MD    212-241-6770    amy.yang@mssm.edu   
Contact: Chanan Stauffer, MS, RN    703-597-6777    Chanan78@gmail.com   
Australia, Victoria
Royal Melbourne Hospital
Parkville, Victoria, Australia, 3050
Contact: Donna North    +61 03 934 24219    donna.north@mh.org.au   
Principal Investigator: Kathleen Nicholls, MD         
Sponsors and Collaborators
Amicus Therapeutics
Investigators
Study Director: Medical Monitor, Clinical Research Amicus Therapeutics
  More Information

Responsible Party: Amicus Therapeutics
ClinicalTrials.gov Identifier: NCT01476163     History of Changes
Other Study ID Numbers: AT1001-188 
Study First Received: November 17, 2011
Last Updated: November 9, 2016
Health Authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
United States: Food and Drug Administration

Keywords provided by Amicus Therapeutics:
AT1001
Lysosomal storage disease
Lysosomal Storage Disorder
migalastat
Fabry disease
Fabry
Amicus

Additional relevant MeSH terms:
Fabry Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on December 02, 2016